A Single Dose Study to Compare the Pharmacokinetics of Two Probe Formulations of MK-1006.
Phase of Trial: Phase I
Latest Information Update: 24 Dec 2014
At a glance
- Drugs MK 1006 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Merck & Co
- 24 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 18 Nov 2009 Planned end date changed from 1 Dec 2009 to 1 Dec 2009 as reported by ClinicalTrials.gov.